Please login to the form below
Bioequivalence study triggers milestone payment for Eurand
Eurand completes a bioequivalence study with GlaxoSmithKline regarding an undisclosed GSK compound
Eurand, an Italian/ US-based specialty pharmaceutical company, has successfully completed a bioequivalence study with GlaxoSmithKline (GSK), regarding an undisclosed GSK compound.
UK-headquartered GSK will make a payment of USD 1.5m to Eurand in recognition of the milestone.
The new formulation, which uses Eurand's Microcaps and AdvaTab technologies, is designed to dissolve quickly in the mouth to reduce the bitter taste of some medications. Eurand could potentially receive milestone payments from GSK totalling up to USD 42m for the development of the product. GSK expects to file an NDA in the near future.
Under the agreement, Eurand will manufacture the product for GSK and receive royalty revenues when the product receives NDA approval from the FDA.
Gearoid Faherty, CEO of Eurand, said: "We are delighted with the results of the bio-study and are looking forward to GSK submitting their NDA."
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Associate Director
-
£75, 000-90, 000
- Global Business Development Director – Health Education
-
excellent commission
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Business Director
-
Competitive Salary Offered
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
- Evenity back on track with FDA panel blessing in osteoporosis
PMHub
M&F Health
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...
Latest intelligence
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
